Teriflunomide attenuates immunopathological changes in the Dark Agouti rat model of experimental autoimmune encephalomyelitis

Teriflunomide is an oral disease-modifying therapy recently approved in several locations for relapsing forms of multiple sclerosis. To gain insight into the effects of teriflunomide, immunocyte population changes were measured during progression of experimental autoimmune encephalomyelitis in Dark...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Garth E. Ringheim, Lan eLee, Lynn eLaws-Ricker, Thomas eDelohery, Li eLiu, Donghui eZhang, Nicholas eColletti, Timothy J Soos, Kendra eSchroeder, Barbara eFanelli, Nian eTian, Christopher W Arendt, Deborah eIglesias-Bregna, Margaret ePetty, Zhongqi eJi, George eQian, Rajula eGaur, Daniel eWeinstock, Jean eCavallo, Juventas eTelsinskas, Kathleen eMcMonagle-Strucko
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2013-10-01
coleção:	Frontiers in Neurology
Assuntos:	Lymphocytes Multiple Sclerosis Experimental autoimmune encephalomyelitis teriflunomide dihydro-orotate dehydrogenase
Acesso em linha:	http://journal.frontiersin.org/Journal/10.3389/fneur.2013.00169/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!